Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences indefinite-lived IPR&D intangible assets ($M) ($M)
Form 10-Q / 10-K Note 9 Goodwill and Intangible Assets
Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
-100.0%
2,700 in Q2 2025
History
29 quarters
Since Q1 2014
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Indefinite-lived IPR&D intangible assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 0 | -100.0% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,300 | -20.4% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,300 | -20.4% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,700 | -6.6% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,700 | -41.8% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,890 | -37.7% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,890 | -59.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,890 | – | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,640 | – | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,640 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 7,070 | -46.5% | Form 10-K (filed 2025-02-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 13,220 | -17.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q4 2021 | Dec 31, 2021 | 15,920 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q4 2018 | Dec 31, 2018 | 0 | -100.0% | Form 10-K (filed 2019-02-26) ↗ |
| Q2 2018 | Jun 30, 2018 | 2,750 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 2,750 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,750 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q4 2016 | Dec 31, 2016 | 0 | -100.0% | Form 10-K (filed 2018-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 201 | -53.5% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 318 | -26.4% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 318 | -26.4% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 432 | 0.0% | Form 10-K (filed 2017-02-27) ↗ |
| Q3 2015 | Sep 30, 2015 | 432 | -0.1% | Form 10-Q (filed 2015-11-04) ↗ |
| Q2 2015 | Jun 30, 2015 | 432 | -25.7% | Form 10-Q (filed 2015-08-05) ↗ |
| Q1 2015 | Mar 31, 2015 | 432 | -25.7% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 432 | – | Form 10-K (filed 2016-02-24) ↗ |
| Q3 2014 | Sep 30, 2014 | 432 | – | SEC Filing ↗ |
| Q2 2014 | Jun 30, 2014 | 582 | – | SEC Filing ↗ |
| Q1 2014 | Mar 31, 2014 | 582 | – | SEC Filing ↗ |
Breakdown
What makes up indefinite-lived ipr&d intangible assets ($m)
Cite this data
StockData. (2026). Gilead Sciences Indefinite-lived IPR&D intangible assets ($M) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_indef_net
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.